Blockchain Registration Transaction Record

VolitionRx Unveils Breakthrough Capture-Seq™ for 100% Accurate Cancer Detection

VolitionRx announces Capture-Seq™, a new liquid biopsy method achieving 100% accuracy in early cancer detection via enriched DNA fragment analysis in blood samples.

This development represents a potential paradigm shift in oncology. Current cancer screening methods like colonoscopies or mammograms can be invasive, expensive, and have variable accuracy, especially for early-stage disease. Liquid biopsies that analyze circulating tumor DNA (ctDNA) have emerged as a promising non-invasive alternative, but they often struggle with low signal-to-noise ratios, making early detection difficult. Volition's Capture-Seq™ method directly addresses this core technical hurdle with its 180-fold enrichment, enabling the detection of ultrashort DNA fragments bound to transcription factors. The reported 100% sensitivity and specificity in an initial cohort, if validated in larger studies, could lead to a simple blood test capable of detecting multiple cancers at their earliest, most treatable stages. This would dramatically improve survival rates, reduce healthcare costs associated with late-stage treatment, and alleviate patient anxiety through less invasive monitoring. It positions Volition at the forefront of the multi-billion dollar liquid biopsy market, with implications for personalized medicine and population-wide cancer screening programs.